Free Trial

CytoMed Therapeutics (GDTC) Competitors

CytoMed Therapeutics logo
$1.96 -0.06 (-2.74%)
Closing price 09/3/2025 03:58 PM Eastern
Extended Trading
$1.94 -0.02 (-0.77%)
As of 09/3/2025 05:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GDTC vs. ATNFW, LBPSW, AEHAW, AIMDW, ALVOW, ARAV, ACABW, BFRIW, BTMDW, and BCTXW

Should you be buying CytoMed Therapeutics stock or one of its competitors? The main competitors of CytoMed Therapeutics include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), Aravive (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), and BriaCell Therapeutics (BCTXW). These companies are all part of the "pharmaceutical products" industry.

CytoMed Therapeutics vs. Its Competitors

180 Life Sciences (NASDAQ:ATNFW) and CytoMed Therapeutics (NASDAQ:GDTC) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk.

180 Life Sciences has higher earnings, but lower revenue than CytoMed Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
180 Life SciencesN/AN/AN/AN/AN/A
CytoMed Therapeutics$50KN/A-$1.84MN/AN/A

0.0% of CytoMed Therapeutics shares are held by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, CytoMed Therapeutics had 3 more articles in the media than 180 Life Sciences. MarketBeat recorded 3 mentions for CytoMed Therapeutics and 0 mentions for 180 Life Sciences. CytoMed Therapeutics' average media sentiment score of 0.92 beat 180 Life Sciences' score of 0.00 indicating that CytoMed Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
180 Life Sciences Neutral
CytoMed Therapeutics Positive

CytoMed Therapeutics has a consensus target price of $5.00, indicating a potential upside of 155.75%. Given CytoMed Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe CytoMed Therapeutics is more favorable than 180 Life Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
180 Life Sciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
CytoMed Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Company Net Margins Return on Equity Return on Assets
180 Life SciencesN/A N/A N/A
CytoMed Therapeutics N/A N/A N/A

Summary

CytoMed Therapeutics beats 180 Life Sciences on 7 of the 7 factors compared between the two stocks.

Get CytoMed Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for GDTC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GDTC vs. The Competition

MetricCytoMed TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market CapN/A$3.11B$5.77B$9.76B
Dividend YieldN/A2.28%6.66%4.49%
P/E RatioN/A21.1082.3826.60
Price / SalesN/A357.27498.43159.38
Price / CashN/A43.5325.7028.92
Price / Book3.208.1311.056.56
Net Income-$1.84M-$53.35M$3.28B$266.04M
7 Day Performance-3.69%0.73%0.12%-0.89%
1 Month Performance5.11%7.76%8.96%4.34%
1 Year Performance31.21%11.97%53.91%24.06%

CytoMed Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GDTC
CytoMed Therapeutics
2.3233 of 5 stars
$1.96
-2.7%
$5.00
+155.8%
+18.5%$0.00$50K0.00N/APositive News
ATNFW
180 Life Sciences
N/A$0.26
-5.4%
N/A+1,961.9%$0.00N/A0.007Gap Down
LBPSW
4D pharma
N/AN/AN/AN/A$0.00$522K0.00N/A
AEHAW
Aesther Healthcare Acquisition
N/A$0.00
flat
N/AN/A$0.00N/A0.002
AIMDW
Ainos
N/A$0.35
+45.6%
N/AN/A$0.00$110.87K0.0040Positive News
ALVOW
Alvotech
N/A$1.23
+5.3%
N/A-56.1%$0.00$560.10M0.004Positive News
ARAV
Aravive
N/A$0.04
flat
N/AN/A$0.00$9.14M0.0020High Trading Volume
ACABW
Atlantic Coastal Acquisition Corp. II
N/A$0.03
+6.5%
N/A-6.5%$0.00N/A0.0015
BFRIW
Biofrontera
N/A$0.15
+7.4%
N/A+201.8%$0.00$39.19M0.0070
BTMDW
biote
N/A$0.01
+22.1%
N/A-96.2%$0.00$199.07M0.00N/A
BCTXW
BriaCell Therapeutics
N/A$0.02
-2.9%
N/A-88.0%$0.00N/A0.008Short Interest ↓
Gap Down

Related Companies and Tools


This page (NASDAQ:GDTC) was last updated on 9/4/2025 by MarketBeat.com Staff
From Our Partners